Understanding how specific proteins interact to prevent lung cancer growth
Pdcd4-Rictor Interaction in Suppression of Lung Tumorigenesis
['FUNDING_R01'] · UNIVERSITY OF KENTUCKY · NIH-10932407
This study is looking at how two proteins work together to help stop lung tumors from growing, with the goal of finding new treatments that could make a real difference for people with lung cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-10932407 on ClinicalTrials.gov |
What this research studies
This research investigates the interaction between two proteins, Pdcd4 and Rictor, to understand how they can suppress the growth of lung tumors. By studying the mechanisms that lead to lung cancer, particularly focusing on the mTORC2 pathway, the research aims to identify new therapeutic approaches that could improve treatment outcomes for patients. The team will use various biological assays and models to explore how inhibiting this interaction can affect cancer cell proliferation and survival. This could lead to the development of targeted therapies that are more effective against lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), particularly those with Rictor gene amplification.
Not a fit: Patients with lung cancer types not related to Rictor amplification or those with advanced-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for lung cancer patients.
How similar studies have performed: Other research has shown promising results in targeting the mTOR pathway for cancer treatment, suggesting that this approach may be effective.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YANG, HSIN-SHENG — UNIVERSITY OF KENTUCKY
- Study coordinator: YANG, HSIN-SHENG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.